骨髓纤维化患者移植后环磷酰胺预防移植物抗宿主病后植入不良
该研究比较了2016至2023年间首次接受异基因造血细胞移植的骨髓纤维化患者,采用移植后环磷酰胺(PTCY)方案(49例)与未采用PTCY方案(89例)预防移植物抗宿主病的临床结局。PTCY组中性粒细胞植入时间中位数为D+18,未采用PTCY组为D+15(p<0.0001);血小板恢复时间中位数分别为D+33.5和D+26(p=0.0006);PTCY组需要供者淋巴细胞输注、CD34补充或二次移植的比例显著更高(1年时33% vs 13%,p=0.004)。PTCY与植入延迟、供者粒细胞嵌合率降低及需要额外供者细胞输注增加相关,但未影响生存。
要点
- PTCY组中性粒细胞植入中位时间为D+18,未采用PTCY组为D+15(p<0.0001)。
- PTCY组血小板恢复中位时间为D+33.5,未采用PTCY组为D+26(p=0.0006)。
- PTCY组1年时需要供者淋巴细胞输注、CD34补充或二次移植的比例为33%,未采用PTCY组为13%(p=0.004)。
核心结论
- 在骨髓纤维化患者中,采用PTCY预防GVHD与植入延迟、供者粒细胞嵌合率降低及移植后需要额外供者细胞输注增加相关,但未影响生存。
研究设计与样本
- 研究比较了2016年至2023年间首次接受异基因造血细胞移植的骨髓纤维化患者,接受PTCY方案(N=49)与未接受PTCY方案(N=89)预防GVHD的临床结局。
主要发现
- 在植入患者中,PTCY组中性粒细胞植入中位时间为D+18,未采用PTCY组为D+15(p<0.0001)。
- PTCY组血小板恢复中位时间为D+33.5,未采用PTCY组为D+26(p=0.0006)。
- PTCY组植入失败率为27%,未采用PTCY组为15%,差异未达统计学显著(p=0.095)。
- PTCY组1年时需要供者淋巴细胞输注、CD34补充或二次移植的比例为33%,未采用PTCY组为13%(p=0.004)。
- PTCY组D+100时粒细胞嵌合率≥90%的患者比例为76%,未采用PTCY组为98.2%(p=0.0028)。
关键数值与推荐
- PTCY组慢性GVHD发生率显著低于未采用PTCY组(p=0.0002)。
- 两组其他结局相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with myelofibrosis (MF) often have impaired engraftment after allogeneic hematopoietic cell transplantation (alloHCT). To determine whether posttransplant cyclophosphamide (PTCY) exerts a detrimental impact on engraftment, we compared clinical outcomes of all patients receiving PTCY (N = 49) and no-PTCY (N = 89) regimens as GVHD prophylaxis after first alloHCT for MF from 2016 to 2023. Median age was 64 in both groups, and baseline characteristics were balanced except that the PTCY group received more haploidentical transplants and were more likely to have secondary MF. Among engrafted individuals, median time to neutrophil engraftment was D + 18 for PTCY and D + 15 for no-PTCY (p < 0.0001). Median time to platelet recovery was D + 33.5 and D + 26 for PTCY and no-PTCY, respectively (p = 0.0006). The graft failure rate was higher for PTCY but did not reach statistical significance (27% for PTCY and 15% for non-PTCY, p = 0.095). The need for donor lymphocyte infusion, CD34 boost, or second transplant was significantly higher for PTCY (33% vs. 13% at 1-year, respectively, p = 0.004). Most cases of graft failure in both cohorts were due to prolonged cytopenias in the absence of relapse. While T-cell chimerism at D + 30 and D + 100 was robust after PTCY, the proportion of patients with granulocyte chimerism ≥ 90% at Day + 100 was significantly lower in PTCY (76% vs. 98.2%, respectively, p = 0.0028). All other outcomes were similar except for a significantly lower chronic GVHD rate in PTCY compared with no-PTCY (p = 0.0002). GVHD prophylaxis with PTCY in patients with MF is associated with delayed engraftment, lower donor granulocyte chimerism, and increased need for additional donor cell infusions after transplant without compromising survival.
引用
- Kim HT, Liney DJ, Rizza K, et al. Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Myelofibrosis. Am J Hematol. 2025. PMID: 40509708. doi:10.1002/ajh.27741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。